top
Search terms
Results 1 - 10 of 11 - ordered by :
Pages: 1 2
Epeuropace

Phase I, baseline cohort before the introduction of non-VKA oral anticoagulants (NOACs); Phase II, just after the introduction of the first NOAC dabigatran, with 2-year follow-up in ...

Europace, CLINICAL RESEARCH, Menno V. Huisman, Chang Sheng Ma, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kenneth J. Rothman, Christine Teutsch, Nils Schoof, Eva Kleine, Dorothee ...

Date : 01/09/2016 Item size : 261631 bytes
Epeuropace

Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot ...

Europace, CLINICAL RESEARCH, Gregory Y.H. Lip, Cécile Laroche, Mircea Iaochim Popescu, Lars Hvilsted Rasmussen, Laura Vitali-Serdoz, Gheorghe-Andrei Dan, Zbigniew Kalarus, Harry J.G.M. Crijns, ...

Date : 01/12/2015 Item size : 284192 bytes
Epeuropace

Over time many stroke risk stratification schema have been developed, initially with the objective to better define high-risk patients who could be subjected to an inconvenient (and potentially ...

Europace, Editorial, Ron Pisters, Jonas B. Olesen, Gregory Y.H. Lip

Date : 01/01/2012 Item size : 140103 bytes
Epeuropace

The CHA2DS2-VASc schema for stroke risk assessment C Congestive heart failure/LV dysfunction 1 H Hypertension 1 A Age 75 2 D Diabetes mellitus 1 S Stroke/TIA/TE 2 V Vascular disease (prior myocardial ...

Europace, Corrigendum, Laurent Fauchier, Gregory Y.H. Lip

Date : 01/09/2010 Item size : 101568 bytes
Ehjournal

If a VKA is used, good quality anticoagulation control, defined as a time in therapeutic range (TTR) >70%, is crucial, given that the efficacy and (particularly) safety of VKA is intimately related ...

European Heart Journal, Editorial, Gregory Y.H. Lip, Deirdre A. Lane

Date : 07/12/2015 Item size : 179987 bytes
Epeuropace

When a clinician has to decide on use of antithrombotic drugs in the setting of a patient affected by atrial fibrillation (AF) experiencing an acute coronary syndrome (ACS), the difficult task is ...

Europace, Editorial, Giuseppe Boriani, Deirdre A. Lane, Stephan Windecker, Kurt Huber, Paulus Kirchhof, Gregory Y.H. Lip

Date : 01/09/2015
Ehjournal

Abstract Background The EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot) provides systematic collection of contemporary data regarding the ...

European Heart Journal, Fast Track ESC Clinical Trial and Registry Update, Gregory Y.H. Lip, Cécile Laroche, Popescu Mircea Ioachim, Lars Hvilsted Rasmussen, Laura Vitali-Serdoz, Lucian Petrescu, ...

Date : 14/12/2014
Epeuropace

Dual antiplatelet therapy, in contrast, is recommended after coronary artery stenting to reduce the increased risk of stent thrombosis.3 Oral anticoagulant therapy is less effective after stenting,4 ...

Europace, Editorial, Francisco Marín, Paulus Kirchhof, Gregory Y.H. Lip

Date : 01/07/2009
Epeuropace

Abstract This EP Wire surveyed clinical practice with regard to the use of antithrombotic therapy in relation to device implantation (pacemakers, ICT, resynchronization therapy) and atrial ...

Europace, EP WIRE, Gregory Y.H. Lip, Alessandro Proclemer, Nikolaus Dagres, Maria Grazia Bongiorni, Thorsten Lewalter, Carina Blomstrom-Lundqvist

Date : 01/05/2012
Ehjcvp

Methods and results In this observational study, 5426 Chinese AF patients (77.7 ± 10.7 years, female: 53.1%) with a CHA2DS2-VASc score of 1 were included in the final analysis: of which, 3832 ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Pak-Hei Chan, Wen-Hua Li, Jo-Jo Hai, Koon-Ho Chan, Hung-Fat Tse, Bernard Man-Yung Cheung, Esther W. Chan, Ian C.K. Wong, ...

Date : 01/10/2015